Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit is substantial in the second-line treatment of ALK+ advanced non-small cell lung cancer (NSCLC). |
Clinical Added Value
| moderate |
XALKORI provides a moderate improvement in actual benefit (level III) in the treatment strategy of ALK+ advanced non-small cell lung cancer as a second-line therapy and compared with docetaxel or pemetrexed. |
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
7evCYKKJY0J7Wt0R
